Difference between revisions of "Cisplatin (Platinol)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Basal cell carcinoma (BCC)" to "Cutaneous basal cell carcinoma") |
Warner-admin (talk | contribs) m (Text replacement - "Squamous cell carcinoma (SCC)" to "Cutaneous squamous cell carcinoma") |
||
| Line 39: | Line 39: | ||
*[[SCC of unknown primary]] | *[[SCC of unknown primary]] | ||
*[[Small cell lung cancer]] | *[[Small cell lung cancer]] | ||
| − | *[[ | + | *[[Cutaneous squamous cell carcinoma]] |
*[[Testicular cancer]] | *[[Testicular cancer]] | ||
*[[Thymoma]] | *[[Thymoma]] | ||
| Line 175: | Line 175: | ||
[[Category:SCC of unknown primary medications]] | [[Category:SCC of unknown primary medications]] | ||
[[Category:Small cell lung cancer medications]] | [[Category:Small cell lung cancer medications]] | ||
| − | [[Category: | + | [[Category:Cutaneous squamous cell carcinoma medications]] |
[[Category:Testicular cancer medications]] | [[Category:Testicular cancer medications]] | ||
[[Category:Thymoma medications]] | [[Category:Thymoma medications]] | ||
Revision as of 19:39, 16 August 2018
General information
Class/mechanism: Platinum analog, alkylating-like, producing predominantly interstrand DNA crosslinks that are cell-cycle nonspecific.[1][2]
Route: IV, intracavitary (intraperitoneal)
Extravasation: vesicant (concentration ≥0.5 mg/mL)/irritant (concentration <0.5 mg/mL)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Adenocarcinoma of unknown primary
- Adrenocortical carcinoma
- Anal cancer
- Anaplastic large cell lymphoma
- Cutaneous basal cell carcinoma
- Bladder cancer
- Breast cancer
- Cervical cancer
- Cholangiocarcinoma
- Diffuse large B-cell lymphoma
- Esophageal cancer
- Extranodal NK/T-cell lymphoma, nasal type
- Gastric cancer
- Head and neck cancer
- Hepatobiliary cancer
- Hodgkin lymphoma
- Low-grade glioma
- Mantle cell lymphoma
- Melanoma
- Mesothelioma
- Multiple myeloma
- Nasopharyngeal carcinoma
- Non-small cell lung cancer
- Osteosarcoma
- Ovarian cancer
- Pancreatic cancer
- Penile cancer
- Peripheral T-cell lymphoma
- Primary mediastinal B-cell lymphoma
- SCC of unknown primary
- Small cell lung cancer
- Cutaneous squamous cell carcinoma
- Testicular cancer
- Thymoma
- Transformed lymphoma
- Uterine cancer
Patient drug information
- Cisplatin (Platinol) patient drug information (Chemocare)[3]
- Cisplatin (Platinol) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 12/19/1978: Initial FDA approval
Also known as
- Code name: NSC 119875
- Generic names: CDDP, cis-diamminedichloroplatinum III, cis-platinum, cisplatinum, DACP, DDP
- Brand names:
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Abiplatin | Axiplat | Biocisplatinum | Bioplatino | Blastolem | Briplatin | Brisplatin | C-Platin |
| Ceplatin | Ciplatan | Ciplexal | Cis-GRY | Cismaplat | Cispatin | Cisplamerck | Cisplan |
| Cisplasol | Cisplatex | Cisplatine | Cisplatino | Cisplatyl | Cisteen | Citoplatino | Cytoplatin |
| Docistin | Elvecis | Fauldcispla | Ifapla | Kemoplat | Lederplatin | Metaplatin | Neoplat |
| Neoplatin | Noveldexis | Oncoplatin AQ | Placis | Platamin | Platamine | Platiblastin | Platicis |
| Platidiam | Platikem | Platil | Platimit | Platin | Platinil | Platino II Filaxis | Platinol |
| Platinox | Platinoxan | Platiran | Platistil | Platistin | Platistine | Platosin | Randa |
| Romcis | Sicatem | Sinplatin | Sisplanil | Tecnoplatin | Tisplal | Unistin | |
References
Categories:
- Drugs
- Intravenous medications
- Intracavitary medications
- Vesicant chemotherapy
- Irritant chemotherapy
- Platinum agents
- Alkylating agents
- Adenocarcinoma of unknown primary medications
- Adrenocortical carcinoma medications
- Anal cancer medications
- Anaplastic large cell lymphoma medications
- Cutaneous basal cell carcinoma medications
- Bladder cancer medications
- Breast cancer medications
- Cervical cancer medications
- Cholangiocarcinoma medications
- Diffuse large B-cell lymphoma medications
- Esophageal cancer medications
- Extranodal NK/T-cell lymphoma, nasal type medications
- Gastric cancer medications
- Head and neck cancer medications
- Hepatobiliary cancer medications
- Hodgkin lymphoma medications
- Low-grade glioma medications
- Mantle cell lymphoma medications
- Melanoma medications
- Mesothelioma medications
- Multiple myeloma medications
- Nasopharyngeal carcinoma medications
- Non-small cell lung cancer medications
- Osteosarcoma medications
- Ovarian cancer medications
- Pancreatic cancer medications
- Penile cancer medications
- Peripheral T-cell lymphoma medications
- Primary mediastinal B-cell lymphoma medications
- SCC of unknown primary medications
- Small cell lung cancer medications
- Cutaneous squamous cell carcinoma medications
- Testicular cancer medications
- Thymoma medications
- Transformed lymphoma medications
- Uterine cancer medications
- FDA approved in 1978
- WHO Essential Cancer Medicine